A study by Friedlander et al. [12] described no significant differences in survival rates between the two age groups.
In contrast, Table 5 describes no significant difference over the years in discussing alcohol use (compared to 1975).
The remaining literature describes no significant differences in complication rates between simultaneous and two-stage bilateral THA.
However, in the same report, Lanzrein et al. describe no significant differences between AD subjects and controls regarding serum and CSF levels of interleukin-1 beta (IL-1 β), IL-1 receptor antagonist (IL-1ra), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- α), the soluble TNF receptors type I and II (sTNFR 1 and 2), and the acute phase protein alpha1-antichymotrypsin (α1-ACT).
Our study does support a previous finding by Hwang et al. [ 17], who described no significant survival differences between HCC patients with chronic HBV (positive HBsAg) and HCC patients with HCV (positive anti-HCV).
As opposed to the metabolites described in the previous paragraph, no significant differences were detected for lactate and BHIB when both CIS patient groups were pooled together and compared to controls (Table 2).
Furthermore, as describe here we report no significant difference in utility scores for PF regorafenib-treated patients compared to placebo (p = 0.233) within the same health state, suggesting similar QoL in the two groups.
The effects of oxidative stress were checked at different stages of the experiment as previously described, and no significant differences were found between the four experimental groups and the blank control group until 66th day.
When beads are made as described above, no significant differences in ethanol production, substrate consumption or fermentation parameters are found when using different initial bead diameters.
